NYSE:VOR

Vor Biopharma (VOR) Stock Forecast, Price & News

$4.70

+0.12 (+2.62%)

(As of 05/31/2023 ET)

Compare

Today's Range: $4.54
▼
$4.91
50-Day Range: $3.85
▼
$5.88
52-Week Range: $3.48
▼
$7.57

Volume: 84,901 shs
Average Volume: 115,281 shs
Market Capitalization: $314.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.19

Vor Biopharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 244.4% Upside
$16.19 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.28
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.76) to ($1.86) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

470th out of 1,006 stocks

4.5

Analyst's Opinion

Consensus Rating
Vor Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.19, Vor Biopharma has a forecasted upside of 244.4% from its current price of $4.70.
Amount of Analyst Coverage
Vor Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for VOR.

0.0

Dividend Strength

Dividend Yield
Vor Biopharma does not currently pay a dividend.
Dividend Growth
Vor Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VOR.

2.1

News and Social Media Coverage

News Sentiment
Vor Biopharma has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Vor Biopharma this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for VOR on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
3 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vor Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.40% of the stock of Vor Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Vor Biopharma are expected to decrease in the coming year, from ($1.76) to ($1.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vor Biopharma is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vor Biopharma is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Vor Biopharma (NYSE:VOR) Stock

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive VOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter.

VOR Stock News Headlines

May 30, 2023 | americanbankingnews.com

Brokerages Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $15.93

May 25, 2023 | uk.finance.yahoo.com

VOR - Vor Biopharma Inc.

June 1, 2023 | Stansberry Research (Ad)

The gold catalyst we've waited for

Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.

May 20, 2023 | americanbankingnews.com

Q2 2023 Earnings Estimate for Vor Biopharma Inc. Issued By HC Wainwright (NYSE:VOR)

May 16, 2023 | msn.com

JonesTrading Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendation

May 16, 2023 | msn.com

Oppenheimer Reiterates Vor Biopharma (VOR) Outperform Recommendation

May 16, 2023 | msn.com

HC Wainwright & Co. Reiterates Vor Biopharma (VOR) Buy Recommendation

May 16, 2023 | markets.businessinsider.com

Vor Biopharma (VOR) Gets a Buy from H.C. Wainwright

June 1, 2023 | Stansberry Research (Ad)

The gold catalyst we've waited for

May 16, 2023 | americanbankingnews.com

Vor Biopharma Inc. to Post FY2027 Earnings of ($0.51) Per Share, Wedbush Forecasts (NYSE:VOR)

May 15, 2023 | markets.businessinsider.com

Oppenheimer Sticks to Their Buy Rating for Vor Biopharma (VOR)

May 15, 2023 | msn.com

8 Analysts Have This to Say About Vor Biopharma

May 12, 2023 | markets.businessinsider.com

Wedbush Reaffirms Their Buy Rating on Vor Biopharma (VOR)

May 12, 2023 | msn.com

Wedbush Reiterates Vor Biopharma (VOR) Outperform Recommendation

May 12, 2023 | markets.businessinsider.com

JMP Securities Remains a Buy on Vor Biopharma (VOR)

May 11, 2023 | de.investing.com

Vor Biopharma: EPS übertrifft Schätzungen um 0,11$ - Umsatz wie erwartet

May 11, 2023 | msn.com

Vor Biopharma GAAP EPS of -$0.43 misses by $0.05

May 11, 2023 | msn.com

Vor Biopharma: Q1 Earnings Insights

May 11, 2023 | finance.yahoo.com

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

May 9, 2023 | americanbankingnews.com

Vor Biopharma (VOR) Set to Announce Earnings on Wednesday

May 5, 2023 | americanbankingnews.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Buy" from Analysts

April 10, 2023 | americanbankingnews.com

Vor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of "Moderate Buy" by Analysts

March 29, 2023 | seekingalpha.com

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

March 29, 2023 | americanbankingnews.com

Vor Biopharma Inc. Expected to Earn Q1 2023 Earnings of ($0.39) Per Share (NYSE:VOR)

March 28, 2023 | finance.yahoo.com

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%

March 28, 2023 | americanbankingnews.com

Vor Biopharma Inc. (NYSE:VOR) Expected to Earn Q1 2024 Earnings of ($0.36) Per Share

March 27, 2023 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Rating Reiterated by Oppenheimer

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter.

VOR Company Calendar

Last Earnings: 3/23/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: N/A
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:VOR
CUSIP: N/A
CIK: 1817229
Web: www.vorbiopharma.com
Phone: N/A
Fax: N/A
Employees: 135
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.19
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +244.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 66,957,000
Free Float: 53,298,000
Market Cap: $314.70 million
Optionable: Not Optionable
Beta: -0.68

Key Executives

Dr. Robert Ang M.B.A. (Age 47)
M.D., MBBS, Pres, CEO & Director
Comp: $744.46k

Dr. Tirtha Chakraborty Ph.D. (Age 49)
Chief Scientific Officer
Comp: $540.64k

Dr. Siddhartha Mukherjee DPHIL (Age 51)
M.D., Ph.D., Scientific Founder & Chairman of Scientific Advisory Board

Dr. Nathan D. Jorgensen M.B.A. (Age 45)
Ph.D., Chief Financial Officer

Ms. Tania Philipp (Age 50)
Chief People Officer

Dr. Robert G. Pietrusko Pharm.D. (Age 74)
Pharm. D., Chief Regulatory & Quality Officer

Mr. John C. King M.B.A. (Age 46)
Chief Commercial Officer

Dr. Veit Schmelmer Ph.D.
Sr. VP of Program & Alliance Management

Dr. Eyal C. Attar M.D. (Age 51)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

VOR Stock - Frequently Asked Questions

Should I buy or sell Vor Biopharma stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vor Biopharma in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VOR shares.
View VOR analyst ratings or view top-rated stocks.
What is Vor Biopharma's stock price forecast for 2023?: 7 brokers have issued 12-month target prices for Vor Biopharma's shares. Their VOR share price forecasts range from $10.00 to $22.00. On average, they anticipate the company's share price to reach $16.19 in the next twelve months. This suggests a possible upside of 244.4% from the stock's current price.
View analysts price targets for VOR or view top-rated stocks among Wall Street analysts.
How have VOR shares performed in 2023?: Vor Biopharma's stock was trading at $6.65 on January 1st, 2023. Since then, VOR stock has decreased by 29.3% and is now trading at $4.70.
View the best growth stocks for 2023 here.
When is Vor Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VOR earnings forecast.
How were Vor Biopharma's earnings last quarter?: Vor Biopharma Inc. (NYSE:VOR) released its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.03.
When did Vor Biopharma IPO?: (VOR) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO.

What is Vor Biopharma's stock symbol?: Vor Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "VOR."
Who are Vor Biopharma's major shareholders?: Vor Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (11.67%), Baker BROS. Advisors LP (0.95%), BlackRock Inc. (0.70%), Ensign Peak Advisors Inc (0.52%), Susquehanna International Group LLP (0.49%) and Geode Capital Management LLC (0.47%). Insiders that own company stock include Kush Parmar and Ventures Vi LP 5Am.
View institutional ownership trends.
How do I buy shares of Vor Biopharma?: Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vor Biopharma's stock price today?: One share of VOR stock can currently be purchased for approximately $4.70.
How much money does Vor Biopharma make?: Vor Biopharma (NYSE:VOR) has a market capitalization of $314.70 million.
How many employees does Vor Biopharma have?: The company employs 135 workers across the globe.

This page (NYSE:VOR) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vor Biopharma (VOR) Stock Forecast, Price & News

Vor Biopharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vor Biopharma (NYSE:VOR) Stock

VOR Stock News Headlines

VOR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

VOR Stock - Frequently Asked Questions

Overall MarketRank^™